On May 13, 2026, the KOSPI opened down -1.69% and slid toward 7,400, before closing at 7,844.01 (+2.63%) — a fresh all-time high. The same session saw foreign investors net-sell ₩3.76tn, absorbed by retail (+₩1.89tn) and domestic institutions (+₩1.69tn). The KOSDAQ printed -0.20%, and breadth was negative — 955 advancers vs. 1,455 decliners in the local DB. This is not a 'broad rally.' It's a compressed large-cap rally. SK hynix +7.68%, Samsung Electro-Mechanics +7.41%, Daeduck Electronics +11.64%, Hyundai Mobis +18.43% — what was working worked harder, and what was lagging stayed flat. The most analytically interesting fact is that the move ignored a full set of risk-off macro inputs — hot US CPI, WTI back above $100, Middle East tension, soft SOX the day before. Macro had its head turned by flow and large-cap news flow.
KOSPI near 7,844 as KR holds Neutral vs US Bull. Six 3-screener overlap candidates led by Gigabis, TES, and Jeju Semiconductor screen for quality re-rating.
The two names at the top of Korea's robotics value chain: Robotis (actuator specialist — hand and joint motion) and Rainbow Robotics (humanoid platform — Samsung Electronics 35% stake). Robotis 2025 revenue ₩38.9bn, OP turn-positive ₩3.4bn, market cap ~₩5.1tn. Rainbow 2025 revenue ₩34.1bn, OP -₩2.5bn (loss), market cap ~₩16.2tn. Rainbow's market cap is 3× Robotis's while revenue is smaller and unprofitable — the gap is the price of the 'Samsung option.' Two distinct questions: for Robotis, 'does the actuator-supplier earnings trajectory deliver?'; for Rainbow, 'does Samsung's robotics strategy convert into revenue?' Both are expensive, but only one is verifiable on a quarterly cadence.
Pearl Abyss's 1Q26 earnings proved Crimson Desert's commercial success and a 64.6% operating margin. The next question is whether the May 21 IR can turn capital allocation, DLC/platform expansion, and DokeV visibility into a higher-quality valuation frame.
A side-by-side of Korea's two most-discussed robot-component names: SPG (reducers — Boston Dynamics, Rainbow Robotics, Samsung, and LG all source from it) and Halla Cast (lightweight die-cast structural parts, recently winning a humanoid-component order from a 'global AI automaker'). SPG sits at the value-chain joint of Korean robotics; Halla Cast supplies its skeleton. SPG market cap ~₩3.0tn at PER ~110×; Halla Cast ~₩620bn at PER ~62×. Both rich, but for different reasons — and the risk shapes differ. SPG: 'core part, so expensive'; risk is 'if expectations don't materialize, the multiple compresses sharply.' Halla Cast: 'option attached, so expensive'; risk is 'if the option doesn't realize, it reverts to an auto-parts multiple.'
The Northern Sea Route is not a finished replacement for Suez. It is a seasonal Asia-Europe shipping option shaped by climate change, geopolitical chokepoints and polar vessel constraints. Korea is moving from talk to execution with a 2026 Busan-Rotterdam trial voyage, Arctic shipping legislation and HMM's relocation to Busan. The structural beneficiaries are less about HMM alone and more about polar shipbuilding, Busan port logistics, marine finance and insurance, green fuel and maritime data infrastructure.
Pearl Abyss delivered 1Q26 earnings alongside its first-ever quantitative annual guidance. Revenue ₩328.5bn, OP ₩212.1bn, OPM 64.6% — OP beat the consensus ₩143.5bn by +48%. More importantly, the company issued formal guidance for the first time: FY26 OP ₩487.6-572.6bn, OPM 55-59%. 2Q Crimson Desert revenue is guided to ₩224.2-276.5bn — a -16% to +4% range vs. 1Q's ₩266.5bn, framing 2Q as plateau, not cliff. This piece breaks down the exact disclosure figures, compares earlier predictions vs. actuals, dissects the OPM 64.6% by cost line, interprets what the company's guidance signals, and lays out forward price triggers.
Korean biotech is not a broad-beta buy regime right now. It is a selection regime where only data-, BD-, royalty-, or CDMO-validated names work. The end of May stacks ASCO (May 29-Jun 2), EASL (May 27-30), and EHA abstract releases (May 12 / Jun 2) into one window. Five theses operate simultaneously: oncology BD (LegoChem Bio, Voronoi, GI Innovation, Lunit), MASH (D&D Pharmatech DD01 48-week biopsy data), SC-conversion royalty platform (Alteogen), CDMO + biosimilars (Samsung Biologics, Celltrion), and the FDA regulatory-innovation long option. The core principle is simple — you are not buying clinical success probability; you are buying *the gap between market-implied success probability and your internal estimate*. FDA biosimilar deregulation and real-time clinical-trials initiative are long-dated options; near-term price is set by the quality of trial data.
The May 12, 2026 intraday selloff and rebound in KOSPI was not just semiconductor volatility. It was the first market test of a larger policy question: who captures the extraordinary profits and tax revenues created by Korea's AI semiconductor supercycle? Kim Yong-beom's AI citizen-dividend framing looks closer to an excess-tax-revenue argument than a direct raid on corporate profits, but the language of excess profits and national dividends was easy for foreign investors to read as a Korea AI windfall-tax risk.